Tag: Drugs

Search News
Categories
Archives
Research highlighted in ASCO annual report on progress against cancer

2nd February 2021

Research led by Professors Peter Schmid and Thomas Powles from Barts Cancer Institute, Queen Mary University of London, has been selected by the American Society of Clinical Oncology (ASCO) for inclusion in the Clinical Cancer Advances 2021, the Society’s annual review of progress against cancer. The notable studies, which investigated the use of immunotherapy in the treatment of triple negative breast cancer and advanced bladder cancer, are featured as two of many remarkable milestones in clinical cancer research and care.

Read more

Chromosomal instability in ovarian cancer

26th November 2020

We spoke with Dr Sarah McClelland and senior postdoctoral researcher in her group, Dr Nadeem Shaikh, about the team’s most recent paper, published in Cancer Research, which set out to explore the mechanisms of chromosomal instability in high-grade serous ovarian carcinoma – the most common type of ovarian cancer. The study sheds light on how these mechanisms may be able to be targeted to overcome treatment resistance in this cancer type.

Read more

London Pancreas Workshop 2020

30th September 2020

On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.

Read more

Results from the Phase I STARPAC trial

24th September 2020

A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.

Read more

Immunotherapy for advanced bladder cancer

18th September 2020

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.

Read more

Investigating new treatment options for mesothelioma

16th September 2020

Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.

Read more

Search News
Categories
Archives